SHANGHAI – Jiangsu Hengrui Medicine Co. Ltd., a billion-dollar integrated pharma with R&D centers in New Jersey, Shanghai and Chengdu, has been pushing in the direction of innovation faster and farther than most other Chinese pharmas. And with the recent announcement they will invest ¥850 million (US$137 million) in a biologics manufacturing plant, it's clear the execs aren't afraid to invest heavily in the high-risk area of large molecules and immunotherapy.